Louis Bock

Lou joined Santé Ventures in 2014 and focuses on biotech deal sourcing and management.

Prior to joining Santé, Lou was Partner and Co-Founder at Scale Venture Partners, where he built the firm’s biotechnology practice. He has also held research, project management, business development and sales roles at Gilead Sciences and Genentech.

Lou has supported eight IPOs for life science companies, which now have a combined market cap exceeding $30 billion. A number of the portfolio companies he has worked with have received FDA approvals and are treating patients for important indications including Adcetris for the treatment of Hodgkin’s Lymphoma, Xenazine for the treatment of Huntington’s disease and Rayos for the treatment of rheumatoid arthritis.

Lou currently serves on the boards of Zogenix (ZGNX) and SkySong Innovations (Arizona State University’s IP Management Company). He has previously been an investor and served on the boards of various other healthcare companies including Horizon Pharma (HZNP), Seattle Genetics (SGEN), Powervision (acquired by Alcon), Molecular Templates (MTEM), Prestwick Pharma (acquired by Biovail) and New Century Hospice (acquired by Curo Health).

Lou earned his MBA in finance from California State University, San Francisco and his BS in biology from California State University, Chico.